Log In
Print this Print this

Obizur, susoctocog alfa (OBI-1)

  Manage Alerts
Collapse Summary General Information
Company Baxalta Inc.
DescriptionRecombinant porcine Factor VIII
Molecular Target Factor VIII
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsTreat acquired hemophilia; Treat acquired hemophilia A; Treat acquired hemophilia A in patients who have developed inhibitory antibodies to human Factor VIII; Treat congenital hemophilia A; Treat hemophilia A; Treat hemophilia A patients refractory to human Factor VIII treatment
Regulatory Designation U.S. - Fast Track (Treat acquired hemophilia A);
EU - Orphan Drug (Treat acquired hemophilia)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today